UK Markets closed

EU clears AstraZeneca's $39bn takeover of rare disease specialist Alexion

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this photo illustration the stock market information of Alexion Pharmaceuticals Inc. seen displayed on a smartphone with the Alexion Pharmaceuticals Inc. logo in the background. (Photo by Igor Golovniov / SOPA Images/Sipa USA)
There is no significant overlap in Alexion and AstraZeneca's portfolio meaning the deal will take the firm into a new part of the market. Photo: Igor Golovniov / SOPA Images/Sipa USA

The EU has given the green light to pharmaceutical giant AstraZeneca's (AZN.L) $39bn (£28.2bn) takeover of rare disease specialist Alexion (ALXN).

In a statement released on Tuesday morning, AstraZeneca said clearance from the European Commission marked "an important step towards completion".

"We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines," said Marc Dunoyer, CFO and executive director of AstraZeneca. "We continue to progress towards the completion of the acquisition during this quarter."

AstraZeneca shares ticked a third of a percent higher in London and Alexion shares were unchanged in the pre-market in New York.

The takeover has already been approved by regulators in the United States, Japan and other countries globally, but is still awaiting clearance from the UK.

The UK's Competition Markets Authority said in May that it is examining the deal after potential antitrust concerns were raised. The watchdog has until 21 July to launch an in-depth inquiry.

Read more: Fortress, Apollo, and CD&R: Inside the private equity firms vying to buy Morrisons

The proposed acquisition, first announced in December 2020, will improve AstraZeneca's scientific presence in immunology. The deal will add five approved medicines and a pipeline of 11 new potential drugs. 

AstraZeneca said that rare diseases represent a high-growth disease area with rapid innovation and significant unmet medical needs. Demand for medicines to treat rare diseases is forecasted to grow by a low double-digit percentage in the future. 

Shareholders of both companies overwhelmingly supported the acquisition in a vote on 11 May 2021.

Watch: What are SPACs?

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting